Home › Rett Syndrome › Pennsylvania › Philadelphia
Rett Syndrome clinical trials in Philadelphia, PA
5 studies for Rett Syndrome are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
RecruitingPhase 3
- Ep0247 21003, Philadelphia
Rett Syndrome Registry
RecruitingObservational study
- Children's Hospital of Philadelphia, Philadelphia
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
RecruitingPhase 3
- Biomed Testing Facility #BIO-17-19104, Philadelphia
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
RecruitingPhase 1/2
- Children's Hospital of Philadelphia, Philadelphia
Neurophysiologic Biomarkers in Rett Syndrome
RecruitingObservational studyHealthy volunteers welcome
- Children's Hospital of Philadelphia, Philadelphia
About Rett Syndrome
Rett syndrome is a rare genetic disease. It causes developmental and nervous system problems, mostly in girls. Learn about symptoms and treatments.
More about Rett Syndrome on MedlinePlus
Rett Syndrome trials in other cities
- Houston, TX5 studies
- Baltimore, MD3 studies
- Los Angeles, CA3 studies
- San Diego, CA3 studies
- Boston, MA3 studies
- Aurora, CO3 studies
- Nashville, TN3 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.